Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Freidberg

Urology Round Rock, TX Medical Doctor

NPI 1295700128 CMS profile 285138

16040 Park Valley Dr Ste 111, Round Rock, TX 78681

Open in the dashboard

General payments

$12,853

530 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Freidberg of Round Rock, TX is reported in the CMS Open Payments database as having received $12,853 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,399 90
2024 General $2,530 79
2023 General $2,356 78
2022 General $1,519 76
2021 General $1,963 99
2020 General $898 51
2019 General $1,189 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Freidberg
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Freidberg were reported at $2,399. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Freidberg Urology median Middle half National median
2019 $1,189 $480 $147–$1,201 $163
2020 $898 $246 $87–$645 $114
2021 $1,963 $358 $111–$1,000 $132
2022 $1,519 $476 $143–$1,263 $149
2023 $2,356 $560 $168–$1,461 $160
2024 $2,530 $563 $170–$1,464 $164
2025 $2,399 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $3,033 91 payments
  2. AbbVie, Inc. $1,548 74 payments
  3. Astellas Pharma US Inc $977 44 payments
  4. Allergan Inc. $613 39 payments
  5. Dendreon Pharmaceuticals LLC $607 23 payments
  6. Sumitomo Pharma America, Inc. $496 26 payments
  7. Pfizer Inc. $471 23 payments
  8. Ferring Pharmaceuticals Inc. $460 15 payments
  9. AstraZeneca Pharmaceuticals LP $424 16 payments
  10. Accord Healthcare, Inc. $423 14 payments
  11. Other $3,799 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,576 526 payments
  2. Education $278 4 payments
Products named General payments · program years 2019–2025
  1. ERLEADA $2,602 83 payments
  2. XTANDI $1,140 53 payments
  3. BOTOX Botox Therapeutic $835 37 payments
  4. BOTOX Hyperhydrosis $725 45 payments
  5. PROVENGE $607 23 payments
  6. ADSTILADRIN $460 15 payments
  7. CAMCEVI $362 11 payments
  8. ORGOVYX $355 17 payments
  9. XIAFLEX $343 24 payments
  10. RYBREVANT $341 3 payments
  11. Other $7,704 342 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

2,136

Median for Urology: 1,053

Drug cost

$3,400,664

Median for Urology: $101,464

Branded share of claims

41.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 112 $1,323,308
Erleada Apalutamide Brand 46 $592,275
Nubeqa Darolutamide Brand 43 $549,334
Orgovyx Relugolix Brand 172 $437,652
Abiraterone Acetate Generic 144 $290,469
Gemtesa Vibegron Brand 122 $102,099
Myrbetriq Mirabegron Brand 74 $66,120
Mirabegron Er Mirabegron Brand 13 $11,214
Tamsulosin Hcl Generic 477 $7,328
Alfuzosin Hcl Er Alfuzosin Hcl Brand 168 $5,073

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$605,143

Of which drugs: $113,424

Medicare patients

1,040

Average age 75

Services billed

19,128

185 women, 855 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 35%
Cancer 35%
Diabetes 32%
Atrial fibrillation 20%
Chronic kidney disease 20%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 3,480 $71,940
Leuprolide injectable, camcevi, 1 mg J1952 Office 12 504 $21,858
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 84 $11,948
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 83 8,400 $793
Injection, ceftriaxone sodium, per 250 mg J0696 Office 19 84 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $1,005
$1,006 46 —
BOTOX
  • AbbVie, Inc. $278
$278 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $82
  • AstraZeneca Pharmaceuticals LP $55
$138 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $103
  • PFIZER INC. $26
$129 172 —
XTANDI
  • Astellas Pharma US Inc $88
  • PFIZER INC. $26
$114 112 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record